Novo Nordisk earmarks $2bn for Chinese “triple G” weight loss shot
Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth…
Metabolic Disorders
-
-
Opko and Entera focus on oral care for obesity and metabolic disorders
Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral…
-
Vivani treats first patient with long-lasting drug implant for weight loss
A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the…
-
Novo Nordisk cuts Wegovy price through new direct-to-patient online pharmacy
Novo Nordisk is introducing a direct-to-patient delivery option for its flagship weight loss drug Wegovy (semaglutide), slashing the price of…
-
Inborn errors of metabolism elicit unique challenges for therapy development
In recent years, major progress has been made in the development of gene therapies for rare diseases. However, research for…
-
Why pharma is still far from a treatment for galactosemia
Nearly three months after an experimental treatment for classic galactosemia was rejected by the US Food and Drug Administration (FDA),…
-
Semaglutide shortage ends as FDA sets deadline for compounders
Compounders are on alert after the US Food and Drug Administration (FDA) declared the shortage of semaglutide –the active ingredient…
-
Super Bowl ad for copycat weight loss drugs stokes pharma power debate
As the Philadelphia Eagles romped to victory against the Kansas City Chiefs in the Super Bowl LIX, the eyes of…
-
Novo Nordisk plans new study for CagriSema, targets 2026 submission
Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential…
-
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks associated with chronic…
